Astellas Venture Management

Astellas Venture Management

Astellas Venture Management

Suggest edits
Follow us
Also headquartered in Menlo Park
Terms of Service Privacy Policy Cookie Statement API Integrations Plans & Pricing
Built with ❤︎ by Datalicious ©2021
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

News

Investments 11

Portfolio

Portfolio Tracker

Add info
Pulse 2.0

Fate Therapeutics Stock Price Increases 37.8%: Why It Happened

Fate Therapeutics Inc
Fate Therapeutics Inc
$79,500,000 Venture capital (Series B)
PE HUB

Oncorus scores $79.5 mln Series B

Oncorus
Oncorus
Xconomy

At Verastem, Infinity’s Former Blood Cancer Drug Heads to FDA

Health
Verastem
Verastem
$38,600,000 Venture capital (Series C)
Xconomy , vcaonline

Effector Raises $38.6M to Advance New Class of Anti-Cancer Drugs

Funding Health Science
Effector Therapeutics
Effector Therapeutics
£4,000,000 Venture capital (Series A)
biospace , FinSMEs

Oncorus Announces Additional Series A Financing Support From Astellas Venture Management LLC

Funding Health
Oncorus
Oncorus
Venture Management
Venture Management
Astellas Venture Management
Astellas Venture Management
Xconomy

Verastem Takes a Low-Cost Flier on Infinity’s Blood Cancer Drug

Health Science
Verastem
Verastem
$37,000,000 Venture capital (Series B)
MedCity News , FinSMEs , Xconomy , +1

Startup targeting protein degradation in cancer raises $37M

Cleave Biosciences
Cleave Biosciences
$43,000,000 Venture capital (Series B)
FinSMEs

Tizona Therapeutics Closes $43M Series B Funding

Health Funding Science
Tizona Therapeutics
Tizona Therapeutics
$40,000,000 Venture capital (Series B)
The San Diego Union-Tribune

Effector Therapeutics raises $40 million

Science Health Funding
Effector Therapeutics
Effector Therapeutics
Xconomy

Verastem Sinks as Mesothelioma Study Halted For Futility

Health